Santhera Pharmaceuticals is to restructure its business and is pursuing options to improve its cash resources after it decided to discontinue the development of its candidate, Puldysa (idebenone), for the treatment of Duchenne muscular dystrophy.
An interim futility analysis indicated Puldysa would be unlikely to meet the primary endpoint of the Phase III SIDEROS study, Santhera explained in an announcement on 6 October. The company...